AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34370916 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental stannous-containing dentifrice (n=43)
Number of subjects: 87
Study 34370916 — intervention group
Group type: COMPARATOR
Intervention: Positive control dentifrice (n=43)
Number of subjects: 87
Study 33636648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg (LEM5)
Number of subjects: 949
Study 33636648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 949
Study 33636648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study 32682347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg melatonin taken 1 hour before desired bedtime for 4 weeks (5-7 nights/week)
Number of subjects: 104
Study 32682347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg melatonin
Number of subjects: 104
Study 32682347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 34989803 — intervention group
Group type: EXPERIMENTAL
Intervention: Razuprotafib BID + latanoprost
Number of subjects: 194
Study 34989803 — intervention group
Group type: EXPERIMENTAL
Intervention: Razuprotafib QD + latanoprost
Number of subjects: 194
Study 34989803 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost monotherapy
Number of subjects: 194
Study 34989803 — intervention group
Group type: EXPERIMENTAL
Intervention: Razuprotafib BID + latanoprost after 14 days
Number of subjects: 194
Study 34989803 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival hyperemia
Number of subjects: 194
Study 33976533 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 25 mg/day
Number of subjects: 0
Study 33976533 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 50 mg/day
Number of subjects: 0
Study 33976533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33976533 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (both dosages)
Number of subjects: 0
Study 33593828 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid immune profile-based signature (LIPS) based on five immune cell subtypes: CD14 high monocytes, CD8+/PD-1 + T cells, plasmacytoid dendritic cells, neutrophils, and CD3 + /CD56 + /CD16 + natural killer (NK)T cells.
Number of subjects: 104
Study 33593828 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid immune profile-based signature (LIPS)
Number of subjects: 104
Study 32898787 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet plus 109 CFU synbiotic supplement (CRS group; n = 45)
Number of subjects: 135
Study 32898787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CRP group; n = 45)
Number of subjects: 135
Study 32898787 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 45) with no intervention
Number of subjects: 135
Study 35864343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Training (VT)
Number of subjects: 65
Study 35864343 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 65
Study 35864343 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 65
Study 32144884 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Arthroplasty (KA) for African American participants
Number of subjects: 384
Study 32144884 — intervention group
Group type: COMPARATOR
Intervention: Knee Arthroplasty (KA) for non-African American participants
Number of subjects: 384
Study 32338441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV)
Number of subjects: 77
Study 32338441 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 77
Study 35715184 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg two times per day for 8 weeks
Number of subjects: 814
Study 35715184 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 814
Study 32677855 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 379
Study 32677855 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin dosing algorithm for patients older than 60
Number of subjects: 379
Study 32677855 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant torasemide
Number of subjects: 379
Study 37676213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 76
Study 37676213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 34959779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-tocopherol 400 IU/day
Number of subjects: 52
Study 34959779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 32548854 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion
Number of subjects: 31
Study 32548854 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline S100B levels in eCHa patients
Number of subjects: 31
Study 32548854 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE levels in active disease phase
Number of subjects: 31
Study 34922865 — intervention group
Group type: EXPERIMENTAL
Intervention: AI classification tool
Number of subjects: 0
Study 34922865 — intervention group
Group type: COMPARATOR
Intervention: Standard interpretation without AI
Number of subjects: 0
Study 34126419 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenhuang Granule (SHG) administered twice a day for 14 days
Number of subjects: 111
Study 34126419 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 111
Study 32092098 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) in conjunction with Propofol patient-controlled sedation (PCS)
Number of subjects: 50
Study 32092098 — intervention group
Group type: COMPARATOR
Intervention: Propofol patient-controlled sedation (PCS) alone
Number of subjects: 50
Study 32092098 — intervention group
Group type: COMPARATOR
Intervention: Both groups (IVR and control)
Number of subjects: 50
Study 33657757 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 46
Study 33657757 — intervention group
Group type: COMPARATOR
Intervention: Suit therapy
Number of subjects: 46
Study 37814228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical radiomics nomogram
Number of subjects: 113
Study 37814228 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 113
Study 37814228 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis (DCA)
Number of subjects: 113
Study 33692176 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive-behavioral therapy (CBT) for severe irritability, with 12 active treatment sessions following a baseline observation period of 2, 4, or 6 weeks.
Number of subjects: 40
Study 33692176 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive-behavioral therapy (CBT) for severe irritability.
Number of subjects: 40
Study 32946574 — intervention group
Group type: EXPERIMENTAL
Intervention: SJX-653 30 mg
Number of subjects: 42
Study 32946574 — intervention group
Group type: EXPERIMENTAL
Intervention: SJX-653 60 mg
Number of subjects: 42
Study 35273276 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention in intervention hospitals
Number of subjects: 6576
Study 35273276 — intervention group
Group type: COMPARATOR
Intervention: Feedback of quality indicators in control hospitals
Number of subjects: 6576
Study 35273276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 6576
Study 34769906 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic resistance exercises with Proprioceptive Neuromuscular Facilitation (PNF) for eight weeks
Number of subjects: 30
Study 34769906 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercises)
Number of subjects: 30
Study 34110494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram Bulk Fill (TB)
Number of subjects: 50
Study 34110494 — intervention group
Group type: COMPARATOR
Intervention: Filtek Ultimate (FU)
Number of subjects: 50
Study 34110494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 33393484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM) for 3 weeks, 45-minute daily sessions
Number of subjects: 60
Study 33393484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 60
Study 33393484 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical therapy only)
Number of subjects: 60
Study 33074729 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin deprivation and LPS injection
Number of subjects: 27
Study 33074729 — intervention group
Group type: EXPERIMENTAL
Intervention: Total insulin deprivation for 9 hours
Number of subjects: 27
Study 33074729 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (OHB) infusion
Number of subjects: 27
Study 33074729 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 27
Study 33074729 — intervention group
Group type: COMPARATOR
Intervention: Insulin-controlled euglycemia
Number of subjects: 27
Study 32444190 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based diabetes education
Number of subjects: 80
Study 32444190 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 80
Study 34984786 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversense real‐time continuous glucose monitoring (CGM) system
Number of subjects: 239
Study 34984786 — intervention group
Group type: COMPARATOR
Intervention: Self‐monitoring of blood glucose or intermittently scanned CGM
Number of subjects: 239
Study 33128696 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents
Number of subjects: 0
Study 33128696 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without RDs)
Number of subjects: 0
Study 32331817 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 369
Study 32331817 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 369
Study 34016544 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐item dry eye questionnaire (DEQ‐5)
Number of subjects: 113
Study 34016544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI)
Number of subjects: 113
Study 34016544 — intervention group
Group type: EXPERIMENTAL
Intervention: McMonnies Dry Eye Questionnaire (MQ)
Number of subjects: 113
Study 34016544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Comfort Index questionnaires (OCI)
Number of subjects: 113
Study 34016544 — intervention group
Group type: EXPERIMENTAL
Intervention: DEQ
Number of subjects: 113
Study 34610929 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based combined resistance and aerobic exercise intervention
Number of subjects: 50
Study 34610929 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 50
Study 36093860 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual embodiment (VE) using an older avatar
Number of subjects: 80
Study 36093860 — intervention group
Group type: COMPARATOR
Intervention: Virtual embodiment (VE) using a younger avatar
Number of subjects: 80
Study 36093860 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger avatar)
Number of subjects: 80
Study 33004472 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin (25 mg)
Number of subjects: 12
Study 33004472 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2409021 (300 mg)
Number of subjects: 12
Study 33004472 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin + LY2409021
Number of subjects: 12
Study 33004472 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2409021
Number of subjects: 12
Study 33004472 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 35143872 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 35 mg orally twice a day for 3 months
Number of subjects: 53
Study 35143872 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 5 mg/kg solution every two days by gavage for two weeks
Number of subjects: 53
Study 35143872 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatments)
Number of subjects: 53
Study 35143872 — intervention group
Group type: COMPARATOR
Intervention: Model group (D-gal 500 mg/kg intraperitoneal injection every two days for six weeks)
Number of subjects: 53
Study 35143872 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 53
Study 34396584 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL lidocaine (2%)
Number of subjects: 8
Study 36050587 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group problem-solving therapy (PST)
Number of subjects: 55
Study 36050587 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 55
Study 32737435 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking frequency
Number of subjects: 0
Study 32737435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea consumption
Number of subjects: 0
Study 32737435 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal alcohol intake frequency ≥ 1/week
Number of subjects: 0
Study 36049147 — intervention group
Group type: EXPERIMENTAL
Intervention: encorafenib (450 mg orally once daily) plus binimetinib (45 mg orally twice daily) until progressive disease -> ipilimumab plus nivolumab (ipilimumab 3 mg/kg once every 3 weeks and nivolumab 1 mg/kg once every 3 weeks × four cycles -> nivolumab 3 mg/kg every 2 weeks)
Number of subjects: 209
Study 36049147 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab plus nivolumab until progressive disease -> encorafenib plus binimetinib
Number of subjects: 209
Study 36049147 — intervention group
Group type: EXPERIMENTAL
Intervention: encorafenib plus binimetinib for 8 weeks -> ipilimumab plus nivolumab until progressive disease -> encorafenib plus binimetinib
Number of subjects: 209
Study 33455924 — intervention group
Group type: EXPERIMENTAL
Intervention: Any depression
Number of subjects: 9856
Study 33455924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 9856
Study 33455924 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, maternal education, paternal occupation, household factors, physical activity, television viewing time
Number of subjects: 9856
Study 33455924 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal education, household composition, fuel use, tobacco use, processed food consumption (boys only)
Number of subjects: 9856
Study 33455924 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-slum urban residence, Muslim religion, household size (girls only)
Number of subjects: 9856
Study 33357217 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (a direct oral anticoagulant)
Number of subjects: 20867
Study 33357217 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 20867
Study 33357217 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 20867
Study 33357217 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty index increase (0.1 increase)
Number of subjects: 20867
Study 34246993 — intervention group
Group type: EXPERIMENTAL
Intervention: SaO2 <93%
Number of subjects: 11093
Study 34246993 — intervention group
Group type: EXPERIMENTAL
Intervention: SaO2 levels outside of 96–97%
Number of subjects: 11093
Study 32712569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 32
Study 32712569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 36498427 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching-based teleoccupational guidance (CTG) over 3 months via WeChat
Number of subjects: 25
Study 36498427 — intervention group
Group type: COMPARATOR
Intervention: Routine teleoccupational guidance (RTG)
Number of subjects: 25
Study 32719097 — intervention group
Group type: EXPERIMENTAL
Intervention: Device that narrows the coronary sinus
Number of subjects: 104
Study 32719097 — intervention group
Group type: COMPARATOR
Intervention: Sham implantation
Number of subjects: 104
Study 32861085 — intervention group
Group type: EXPERIMENTAL
Intervention: TV viewing time
Number of subjects: 2278
Study 32861085 — intervention group
Group type: COMPARATOR
Intervention: Computer, iPad, Phone usage
Number of subjects: 2278
Study 35941676 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5mg/kg
Number of subjects: 26
Study 35941676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 34315974 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machine with a radial basis function kernel
Number of subjects: 488
Study 32636043 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (E-MOB) with a removable orthosis and daily wrist exercises
Number of subjects: 95
Study 32636043 — intervention group
Group type: COMPARATOR
Intervention: Late mobilization (L-MOB) with a standard dorsal plaster cast for 2 weeks followed by a removable orthosis and exercises
Number of subjects: 95
Study 32636043 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (E-MOB)
Number of subjects: 95
Study 32636043 — intervention group
Group type: COMPARATOR
Intervention: Late mobilization (L-MOB)
Number of subjects: 95
Study 35016497 — intervention group
Group type: EXPERIMENTAL
Intervention: TRLB (0.25% bupivacaine 0.4 ml/kg)
Number of subjects: 66
Study 35016497 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 66
Study 33650105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic (NLC) visits
Number of subjects: 656
Study 33650105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic (NLC) visits at 2 months only
Number of subjects: 656
Study 32488902 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen-containing bisphosphonates (N-BPs)
Number of subjects: 4041
Study 34233985 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intermittent theta burst stimulation (iTBS) to the right temporoparietal junction (rTPJ), 600 pulses, 20 sessions over 4 weeks
Number of subjects: 150
Study 34233985 — intervention group
Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS) to the right temporoparietal junction (rTPJ), mimicking the sensation of iTBS without active stimulation
Number of subjects: 150
Study 33900249 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position during heelstick
Number of subjects: 90
Study 33900249 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine on the lap during heelstick
Number of subjects: 90
Study 33900249 — intervention group
Group type: COMPARATOR
Intervention: Supine on the crib (control group) during heelstick
Number of subjects: 90
Study 32078147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 11.5 months
Number of subjects: 74
Study 32078147 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 2.5 months
Number of subjects: 74
Study 34984679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 53452
Study 34984679 — intervention group
Group type: COMPARATOR
Intervention: Chest x-ray (CXR) screening
Number of subjects: 53452
Study 33373914 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol (IPA) inhalation
Number of subjects: 118
Study 33373914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) inhalation
Number of subjects: 118
Study 32087425 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 28
Study 32087425 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study 32185991 — intervention group
Group type: EXPERIMENTAL
Intervention: ZiYin Xiehuo granules (ZYXH)
Number of subjects: 143
Study 32185991 — intervention group
Group type: COMPARATOR
Intervention: Zishen Qinggan granules (ZSQG)
Number of subjects: 143
Study 35556138 — intervention group
Group type: EXPERIMENTAL
Intervention: M-ECT
Number of subjects: 60
Study 35556138 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 60
Study 32653912 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to managed aquifer recharge (MAR) water
Number of subjects: 5745
Study 32653912 — intervention group
Group type: COMPARATOR
Intervention: No access to managed aquifer recharge (MAR) water
Number of subjects: 5745
Study 32647106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed reality (MR) technology assisted lumbar pedicle screws placement
Number of subjects: 50
Study 32647106 — intervention group
Group type: COMPARATOR
Intervention: Traditional lumbar pedicle screws placement
Number of subjects: 50
Study 35134897 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip plus guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study 35134897 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study 35717867 — intervention group
Group type: EXPERIMENTAL
Intervention: MR stimulation (0.4 mg fludrocortisone)
Number of subjects: 116
Study 35717867 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDA-R stimulation (250 mg D-cycloserine)
Number of subjects: 116
Study 35717867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MR/NMDA-R stimulation
Number of subjects: 116
Study 35717867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 32437396 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledgeable informants
Number of subjects: 90
Study 32437396 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected informants
Number of subjects: 90
Study 32437396 — intervention group
Group type: EXPERIMENTAL
Intervention: General perception
Number of subjects: 90
Study 35137532 — intervention group
Group type: EXPERIMENTAL
Intervention: RD-X19
Number of subjects: 31
Study 35137532 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 31
Study 33963372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg per day)
Number of subjects: 12705
Study 33963372 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure lowering treatment
Number of subjects: 12705
Study 32821078 — intervention group
Group type: EXPERIMENTAL
Intervention: Biling Weitong Granules (BLWTG)
Number of subjects: 0
Study 32821078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0